HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes
RecruitingOBSERVATIONAL
Enrollment
2,188
Participants
Timeline
Start Date
August 20, 2024
Primary Completion Date
May 31, 2025
Study Completion Date
August 31, 2025
Conditions
Esophagus CancerGastric CancerHER2-positive CancerHER2-low Cancer
Trial Locations (1)
D08 NHY1
RECRUITING
Trinity St James Cancer Institute, Dublin
All Listed Sponsors
lead
St. James's Hospital, Ireland
OTHER
NCT06550063 - HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes | Biotech Hunter | Biotech Hunter